Vitamin D (25-OH): The Optimal Range Nobody Agrees On

Why Your Lab's 'Normal Range' for Vitamin D May Be Misleading

If you've ever received a vitamin D lab result and been told everything looks fine, only to feel persistently fatigued, catch every cold that goes around, or watch your bone density quietly decline, you are not alone. The standard reference range for serum 25-hydroxyvitamin D — the form measured in a routine blood panel — was originally designed to prevent rickets and osteomalacia, not to support peak immune regulation, cardiovascular health, or cellular repair. That distinction matters enormously in practice.

The Endocrine Society defines vitamin D deficiency as a 25-OH level below 20 ng/mL (50 nmol/L), while insufficiency falls between 20 and 29 ng/mL. Many commercial lab reference ranges extend "normal" all the way up to 100 ng/mL, which creates an enormous gray zone. Meanwhile, a growing body of prospective and interventional research points to a functional sweet spot of roughly 40–60 ng/mL for a wide range of non-skeletal outcomes — a target that fewer than a third of Americans currently reach.

Understanding the difference between "reference range normal" and "vitamin D optimal level" is one of the highest-value things you can do with a standard blood panel. This article walks through the evidence, explains why expert bodies still disagree, and tells you how to interpret your own 25-OH result with confidence.

25-Hydroxy Vitamin D Range: What Every Number Means

Serum 25-hydroxyvitamin D (25-OH D) is the accepted gold-standard marker for vitamin D status. It reflects both dietary intake and cutaneous synthesis from UV-B exposure, and it has a half-life of roughly two to three weeks, making it a reliable snapshot of recent and ongoing exposure.

Here is how the major bodies currently define the range:

The 30 ng/mL cutoff that most physicians use as their target was largely derived from parathyroid hormone suppression studies — the point at which PTH levels plateau, suggesting adequate calcium metabolism (Holick et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21646368). Functional medicine practitioners and a number of academic researchers argue this threshold captures bone health but misses the broader biology of vitamin D's role as a steroid hormone precursor.

Practically, a 25-OH result of 32 ng/mL might look "normal" on your printout while still leaving immune signaling, mood regulation, and insulin sensitivity below their potential operating levels. This is the core of the debate.

Vitamin D Deficiency Threshold: Where the Risk Evidence Is Strongest

The consequences of falling below 20 ng/mL are well-documented and serious. A landmark meta-analysis of 26 prospective cohort studies (n > 65,000 participants) found that individuals in the lowest quintile of 25-OH vitamin D had significantly higher all-cause mortality compared to those in the highest quintile (Schottker et al., BMJ 2014; PMID: 24771005). The association was driven primarily by cardiovascular and cancer mortality, not just fracture risk.

For immune function specifically, vitamin D receptors (VDRs) are expressed on virtually every immune cell, including T cells, B cells, macrophages, and dendritic cells. When 25-OH levels fall below 20 ng/mL, the local conversion to the active hormone calcitriol (1,25-dihydroxyvitamin D) inside immune tissues becomes substrate-limited. A randomized controlled trial in Japanese schoolchildren (n = 334) found that supplementing to raise vitamin D levels significantly reduced influenza A incidence compared to placebo — a 42% relative risk reduction in the primary analysis (Urashima et al., American Journal of Clinical Nutrition 2010; PMID: 20219962).

Cardiovascular risk is another area where the deficiency threshold matters. Low 25-OH vitamin D (< 15 ng/mL) was independently associated with a 62% higher risk of major cardiovascular events in the Framingham Offspring Study (Wang et al., Circulation 2008; PMID: 18180395). The mechanism likely involves vitamin D's role in renin-angiotensin system regulation, endothelial function, and inflammatory cytokine suppression.

For skeletal health, the evidence base is the most mature. Below 20 ng/mL, calcium absorption from the gut decreases substantially, secondary hyperparathyroidism accelerates bone resorption, and the risk of stress fractures and osteoporosis rises measurably.

If you want to understand how nutrient deficiencies show up across multiple body systems simultaneously, the guide to reading comprehensive metabolic panels is a useful companion resource.

Optimal Vitamin D ng/mL: The Research Case for Aiming Higher

This is where the scientific debate gets genuinely interesting — and where the standard "your level is fine" reassurance can fail patients.

Bruce Hollis, PhD, and Carol Wagner, MD, researchers at the Medical University of South Carolina, published seminal work demonstrating that the dose-response curve for vitamin D does not flatten at 30 ng/mL. In a double-blind RCT involving pregnant women, they found that supplementation targeting levels above 40 ng/mL produced significantly better pregnancy outcomes and infant immune profiles than standard supplementation targeting 20–30 ng/mL (Hollis & Wagner, Journal of Bone and Mineral Research 2011; PMID: 21706518).

A separate line of evidence comes from sun-exposed indigenous populations. Studies of Masai and Hadza populations in Tanzania — populations with high outdoor sun exposure year-round — consistently show 25-OH vitamin D levels in the 40–65 ng/mL range, suggesting this may represent a more evolutionarily appropriate baseline than the industrialized median of 20–25 ng/mL.

For metabolic health, research from the VITAL trial and related work suggests meaningful benefits for cancer incidence when levels are maintained above 40 ng/mL. A secondary analysis of VITAL data found that participants with baseline 25-OH vitamin D above 40 ng/mL had a 25% lower risk of advanced cancer compared to those at standard-sufficient levels (Chandler et al., JAMA Network Open 2020; PMID: 32585018).

Neurocognitive function is another dimension. VDRs are densely expressed throughout the brain, including in the hippocampus and prefrontal cortex. Observational data consistently show lower cognitive scores among people with 25-OH levels below 25 ng/mL, though causality from RCTs remains contested in older adults.

For context on how vitamin D interacts with related nutrients in the musculoskeletal system, the vitamin D and bone health explainer covers the calcium-phosphorus-PTH axis in more detail.

Vitamin D Toxicity Level: The Upper Boundary

Given the evidence for aiming higher, a reasonable question is: how high is too high? Vitamin D toxicity (hypervitaminosis D) is real but genuinely rare at the doses required to reach 60–80 ng/mL in most adults.

The Institute of Medicine set a Tolerable Upper Intake Level (UL) of 4,000 IU/day for adults, while acknowledging that clinical toxicity — defined as hypercalcemia with symptoms such as nausea, weakness, polyuria, and kidney stones — is typically not observed below serum levels of 150 ng/mL (375 nmol/L). Most documented cases of toxicity involve accidental ingestion of extremely high doses (>50,000 IU/day for prolonged periods) or manufacturing errors.

A careful analysis of vitamin D safety data published in the American Journal of Clinical Nutrition found that doses up to 10,000 IU/day appear safe for most adults and that toxicity via dietary intake or standard supplementation below that level is "exceedingly rare" (Hathcock et al., AJCN 2007; PMID: 17209171). That said, individuals with granulomatous diseases (sarcoidosis, tuberculosis), primary hyperparathyroidism, or certain lymphomas have impaired regulation of vitamin D activation and can experience hypercalcemia at much lower supplement doses. These populations require medical supervision.

The practical takeaway: the gap between "optimal" (40–60 ng/mL) and "toxic" (> 150 ng/mL) is wide enough that supervised supplementation to reach functional targets carries minimal risk for most healthy adults.

Why Expert Bodies Still Can't Agree

If the evidence for 40–60 ng/mL is compelling, why does the Endocrine Society still use 20 ng/mL as its deficiency cutoff? Several factors explain the gap.

First, the IOM's 2010 Dietary Reference Intake report was explicitly designed around bone health outcomes in healthy populations — it was never intended to define optimal levels for cancer prevention, immune function, or cardiovascular health. The Endocrine Society's 2011 guidelines extended the clinical indications but retained conservative thresholds partly out of concern about over-supplementation at the population level.

Second, large RCTs like VITAL and D-HEALTH were designed to test supplementation (typically 2,000 IU/day) in populations already averaging 25–30 ng/mL at baseline. When a trial starts at near-sufficient levels and adds a fixed dose, the treatment effect is diluted compared to correcting true deficiency. Critics of the "higher is better" argument often cite these null or weak RCT findings without accounting for baseline level confounding.

Third, there is genuine biological variability. People with darker skin pigmentation require more UV-B exposure to synthesize equivalent amounts of vitamin D precursor. Individuals with higher adiposity sequester 25-OH vitamin D in fat tissue, resulting in lower circulating levels despite equivalent synthesis. Genetic variants in the VDR gene, CYP2R1, and GC (vitamin D binding protein) all affect how much free, bioavailable vitamin D an individual has at any given serum concentration. One person's 35 ng/mL may function more like another's 25 ng/mL.

This is precisely why population-level guidelines struggle — and why personalized assessment from an actual blood panel is far more informative than a generic supplement recommendation.

What This Means for Your Formula

When Ones analyzes your 25-OH vitamin D result, it doesn't simply flag levels below 20 ng/mL and move on. The AI evaluates where your level falls relative to the 40–60 ng/mL functional target, weights it alongside other biomarkers (PTH, calcium, magnesium, inflammatory markers), and determines whether supplementation, dose adjustment, or a co-factor intervention is most appropriate.

Two ingredients are central to this:

Vitamin D3 + K2 (MK-7): Ones includes cholecalciferol (D3) paired with menaquinone-7 (MK-7 form of K2) in its personalized formulas. This pairing is not cosmetic — vitamin K2 activates osteocalcin and matrix Gla protein (MGP), proteins that direct calcium into bone and away from arterial walls. Supplementing D3 without K2 when correcting a large deficiency can increase calcium absorption faster than transport proteins route it appropriately. The MK-7 form is preferred for its longer half-life and superior bioavailability compared to MK-4 (Schurgers et al., Blood 2007; PMID: 17158229).

Magnesium Glycinate (via Magnesium Complex): Magnesium is the less-discussed cofactor in vitamin D metabolism. The enzymes responsible for converting vitamin D to its active forms — including CYP27B1, which produces calcitriol — are magnesium-dependent. Studies suggest that approximately 50% of the U.S. population is below the recommended dietary intake for magnesium, and low magnesium can blunt the response to vitamin D supplementation entirely. Ones' Magnesium Complex provides magnesium in glycinate form for superior absorption without the laxative effect common with oxide forms.

The dose of D3 in a Ones formula is calibrated to your specific lab gap, not a fixed population-level amount — which is exactly what the evidence base above suggests is needed.

For a broader look at how micronutrient status interacts across lab panels, the blood panel optimization overview covers the most actionable markers alongside vitamin D.

Key Takeaways

• The standard lab "normal" range for 25-OH vitamin D (≥ 20 ng/mL) was designed to prevent skeletal disease, not to optimize immune, metabolic, or cardiovascular function.
• A growing body of research — including prospective cohort studies and mechanistic RCTs — supports a functional optimal target of 40–60 ng/mL for most adults.
• Vitamin D toxicity is rare below 150 ng/mL; doses up to 10,000 IU/day appear safe for most healthy adults, though granulomatous disease and certain other conditions require medical supervision.
• Individual factors — skin pigmentation, body composition, VDR genetics, and magnesium status — all affect how a given serum level translates to biological activity.
• Vitamin D3 should almost always be paired with vitamin K2 (MK-7 form) to properly direct calcium metabolism during repletion.
• Magnesium is a critical and often overlooked cofactor for vitamin D activation; correcting magnesium deficiency may improve vitamin D response even without changing D3 dose.
• Consult a qualified healthcare provider before making significant changes to your supplementation protocol, especially if you have kidney disease, hyperparathyroidism, or a granulomatous condition.